SPATA17: A Non-Coding RNA Molecule as A Drug Target and Biomarker

Target Name: SPATA17

NCBI ID: G128153

SPATA17

SPATA17: A Non-Coding RNA Molecule as A Drug Target and Biomarker

SPATA17 (SPA-TATA17) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

SPATA17 is a small non-coding RNA molecule that is known for its ability to interact with the protein p16INK4a. This interaction is crucial for the regulation of cell growth and apoptosis, which are critical processes that control cell lifespan and development.

Studies have shown thatSPATA17 can be expressed in various tissues and cells, including cancer cells, and that it plays a role in the regulation of cell growth, apoptosis, and autophagy. It has also been shown to be involved in the development and progression of various diseases, including cancer.

One of the key reasons whySPATA17 has become such an attractive target for drug development is its ability to interact with multiple proteins, including p16INK4a. This makes it difficult for drugs to interact withSPATA17 and inhibit its function, which could lead to the development of drug resistance.

In addition,SPATA17 is also known for its ability to regulate the expression of other genes. This has led to the identification ofSPATA17-regulated genes that are involved in various cellular processes, including cell adhesion, migration, and invasion. This knowledge could potentially lead to the development of new drugs that target these genes.

Another promising aspect ofSPATA17 is its expression pattern. It has been shown to be expressed in various tissues and cells, including cancer cells, and that its levels vary depending on the specific disease state. This could make it an attractive target for personalized medicine, where doctors can tailor treatments to specific individuals based on their individual genetic profiles.

In conclusion,SPATA17 is a non-coding RNA molecule that has shown promise as a drug target and biomarker for various diseases. Its unique structure and function, as well as its ability to interact with multiple proteins and regulate the expression of other genes, make it an attractive target for research and development of new treatments. Further studies are needed to fully understand its role in disease and its potential as a drug.

Protein Name: Spermatogenesis Associated 17

The "SPATA17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPATA17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets